Advertisement

Platelet Transfusion Therapy for Patients with Cancer

  • Charles A. Schiffer
Part of the Cancer Treatment and Research book series (CTAR, volume 13)

Abstract

A number of important advances have occurred in the area of platelet transfusion therapy in recent years. As recently as 10 years ago, the greatest problem in many centers was simply obtaining sufficient numbers of units of platelets for the increasing population of patients with cancer and leukemia being treated more intensively and successfully with newer chemotherapeutic agents. Improvements in bag design and plastics, an increased understanding of the many factors which influence platelets during storage, the development of sophisticated and well organized hospital and regional blood centers and the proliferation of apheresis equipment in these centers, have all helped to make platelets readily available in almost all medical centers. Different problems have arisen however which still limit the effectiveness of platelet transfusions in many patients. In particular, the provision of histocompatible platelets for alloimmunized patients remains a difficult and expensive challenge, and this issue and others will be discussed in this review.

Keywords

Disseminate Intravascular Coagulation Platelet Transfusion Platelet Storage Prophylactic Platelet Transfusion Lymphocytotoxic Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Slichter SJ, Harker LA: Preparation and storage of platelet concentrates. Brit J Haemat 34: 395–402, 1976.PubMedCrossRefGoogle Scholar
  2. 2.
    Murphy S, Gardner FH: Platelet storage at 22°C; metabolic, morphologic and functional studies. J Clin Invest 50: 370–377, 1971.PubMedCrossRefGoogle Scholar
  3. 3.
    Filip DJ, Aster RH: Relative hemostatic effectiveness of human platelets stored at 4°C and 22 °C. J Lab Clin Med 91: 618–624, 1978.PubMedGoogle Scholar
  4. 4.
    Holme S, Vaidja K, Murphy S: Platelet storage at 22 °C: effect of type of agitation on morphology, viability, and function in vitro. Blood 52: 425–436, 1978.PubMedGoogle Scholar
  5. 5.
    Slichter SJ, Harker LA: Preparation and storage of platelet concentrates: II. Storage variables influencing platelet viability and function. Brit J Haemat 34: 403–418, 1976.PubMedCrossRefGoogle Scholar
  6. 6.
    Murphy S, Simon T: Characteristics of prolonged platelet storage in a new container. Transfusion 21: 637, 1981.Google Scholar
  7. 7.
    Kotelba-Witkowska B, Harmening-Pittiglio DM, Schiffer CA: Storage of platelet concentrates using ion exchange resin charged with dibasic phosphate. Blood 58: 537–543, 1981.PubMedGoogle Scholar
  8. 8.
    Schiffer CA: International Forum: What are the parameters to be controlled in platelet concentrates in order that they may be offered to the medical profession as a standardized product with specific properties? Vox Sang 40: 122–124, 1981.Google Scholar
  9. 9.
    Daly PA, Schiffer CA, Aisner J, Wiernik PH: A comparison of platelets prepared by the Haemonetics Model 30 and multiunit bag plateletpheresis. Transfusion 19: 778–781, 1979.PubMedCrossRefGoogle Scholar
  10. 10.
    Hester JP, Kellogg RM, Mulzet AP et al.: Variable anticoagulant (AC) flow rates for plateletpheresis in the dual stage disposable channel. Blood 54 (Suppl 1): 124a, 1979.Google Scholar
  11. 11.
    Katz AJ, Genco PV, Blumberg N et al.: Platelet collection and transfusion using the Fenwal CS-3000 cell separator. Transfusion 21: 560–563, 1981.PubMedCrossRefGoogle Scholar
  12. 12.
    Slichter SJ: Efficacy of platelets collected by semi-continuous flow centrifugation (Haemonetics Model 30). Brit J Haemat 38: 131–140, 1978.PubMedCrossRefGoogle Scholar
  13. 13.
    Aisner J, Schiffer CA, Wolff JH et al.: A standardized technique for efficient platelet and leukocyte collection using the Model 30 Blood Processor. Transfusion 16: 437–445, 1976.PubMedCrossRefGoogle Scholar
  14. 14.
    Schiffer CA, Buchholz DH, Wiernik PH: Intensive multiunit plateletpheresis of normal donors. Transfusion 14: 388–394, 1974.PubMedCrossRefGoogle Scholar
  15. 15.
    Koepke JA, Parks WM, Goeken JA, Klee GG, Strauss RG: The safety of weekly plateletpheresis: effect on the donor’s lymphocyte population. Transfusion 21: 59–62, 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Mielke CH, Kaneshiro MM, Mäher IA et al.: The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34: 204–215, 1969.PubMedGoogle Scholar
  17. 17.
    Harker LA, Slichter SJ: The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 287: 155–159, 1972.PubMedCrossRefGoogle Scholar
  18. 18.
    Schiffer CA, Aisner J, Wiernik PH: Platelet transfusion therapy for patients with leukemia. In: The Blood Platelet in Transfusion Therapy, Greenwalt TJ, Jamieson GA (eds). Alan R. Liss, Inc, New York, 1978, pp 267–279.Google Scholar
  19. 19.
    Higby DJ, Cohen E, Holland JF, Sinks L: The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 14: 440–446, 1974.PubMedCrossRefGoogle Scholar
  20. 20.
    Belt RJ, Leite C, Haas CD et al.: Incidence of hemorrhagic complications in patients with cancer. JAMA 239: 2571–2574, 1978.PubMedCrossRefGoogle Scholar
  21. 21.
    Roy AJ, Jaffe N, Djerassi I: Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 13: 283–290, 1973.PubMedCrossRefGoogle Scholar
  22. 22.
    Dutcher JP, Schiffer CA, Aisner J, O’Connell BA, Levy C, Kendall JA, Wiernik PH: Incidence of thrombocytopenia and bleeding among patients with solid tumors. Cancer. (In press).Google Scholar
  23. 23.
    Solomon J, Bofenkamp T, Fahey JL et al.: Platelet prophylaxis in acute non-lymphoblastic leukemia. Lancet 1: 267, 1978.PubMedCrossRefGoogle Scholar
  24. 24.
    Simpson MB: Platelet function and transfusion therapy in the surgical patient. In: Platelet Physiology and Transfusion, S:hiffer CA (ed). Washington, DC, Amer Assoc Blood Banks, 1978, pp 51–67.Google Scholar
  25. 25.
    Aster RH, Jandl JB: Platelet sequestration in man. I. Methods. J Clin Invest 13: 843–852, 1961.Google Scholar
  26. 26.
    Herzig RH, Herzig GP, Bull MI et al.: Correction of poor platelet transfusion responses with leukocyte poor HLA-matched platelet concentrates. Blood 46: 743, 1975.PubMedGoogle Scholar
  27. 27.
    Silvergleid AJ, Hafleigh EB, Harabin MA et al.: Clinical value of washed-platelet concentrates in patients with non-hemolytic transfusion reactions. Transfusion 17: 33, 1977.PubMedCrossRefGoogle Scholar
  28. 28.
    Alter HJ, Holland PV, Purcell RH et al.: Post-transfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 77: 691, 1972.PubMedGoogle Scholar
  29. 29.
    Barton JC, Conrad ME: Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med 90: 188, 1979.PubMedGoogle Scholar
  30. 30.
    Cohen D, Weinstein H, Mihm M et al.: Nonfatal graft-versus-host disease occurring after transfusion with leukocytes and platelets obtained from normal donors. Blood 53: 1053–1057, 1979.PubMedGoogle Scholar
  31. 31.
    Ford JM, Cullen MH, Lucey JJ et al.: Fatal graft-versus-host disease following transfusion of granulocytes from normal donors. Lancet 2: 1167–1172, 1976.PubMedCrossRefGoogle Scholar
  32. 32.
    Zoes C, Dube VE, Miller HG et al.: Anti-Aj in the plasma of platelet concentrates causing a hemolytic reaction. Transfusion 17: 29, 1977.PubMedCrossRefGoogle Scholar
  33. 33.
    Goldfinger D, McGinniss MH: Rh-incompatible platelet transfusions-risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 284: 942, 1971.PubMedCrossRefGoogle Scholar
  34. 34.
    Schiffer CA, Lichtenfeld JL, Wiernik PH et al.: Antibody response in patients with acute non-lymphocytic leukemia. Cancer 37: 2177–2182, 1976.PubMedCrossRefGoogle Scholar
  35. 35.
    Buchholz DH, Young VM, Friedman NR et al.: Bacterial proliferation in platelet products stored at room temperature. N Engl J Med 285: 429, 1971.PubMedCrossRefGoogle Scholar
  36. 36.
    Silver H, Sonnenwirth AC, Beisser LD: Bacteriologic study of platelet concentrates prepared and stored without refrigeration. Transfusion 10: 315, 1970.PubMedCrossRefGoogle Scholar
  37. 37.
    Katz AJ, Tilton RC: Sterility of platelet concentrates stored at 25 °C. Transfusion 10: 329, 1970.PubMedCrossRefGoogle Scholar
  38. 38.
    Green D, Tiro A, Basiliere J et al.: Cytotoxic antibody complicating platelet support in acute leukemia. JAMA 236: 1044, 1976.PubMedCrossRefGoogle Scholar
  39. 39.
    Howard JE, Perkins HA: The natural history of alloimmunization to platelets. Transfusion 18: 496, 1978.PubMedCrossRefGoogle Scholar
  40. 40.
    Dutcher JP, Schiffer CA, Aisner J et al.: Alloimmunization following platelet transfusion: the absence of a dose response relationship. Blood 57: 395–398, 1980.Google Scholar
  41. 41.
    Holohan TV, Terasaki PI, Deisseroth AB: Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 58: 122–128, 1981.PubMedGoogle Scholar
  42. 42.
    Dutcher JP, Schiffer CA, CA, Aisner J, Wiernik PH: Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood 58: 1007–1011, 1981.PubMedGoogle Scholar
  43. 43.
    Slichter SJ: Controversies in platelet transfusion therapy. Ann Rev Med 31: 509–540, 1980.PubMedCrossRefGoogle Scholar
  44. 44.
    Daly PA, Schiffer CA, Aisner J et al.: Platelet transfusion therapy — one hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 243: 435–438, 1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Hogge D, Dutcher J, Aisner J, Schiffer C: Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematology, (in press).Google Scholar
  46. 46.
    Schiffer CA: Clinical importance of antiplatelet antibody testing for the blood bank. In: A Seminar on Antigens on Blood Cells and Body Fluids, Bell CA (ed). Washington, DC, Am Assoc Blood Banks, 1980, pp 189–208.Google Scholar
  47. 47.
    Brand A, van Leeuwen A, Eernisse JG et al.: Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood 51: 781–788, 1978.PubMedGoogle Scholar
  48. 48.
    Yankee RA, Grumet FC, Rogentine GN et al.: Platelet transfusion therapy. The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 281: 1208–1212, 1969.PubMedCrossRefGoogle Scholar
  49. 49.
    Lohrmann HP, Bull MI, Decter JA et al.: Platelet transfusions from HL-A compatible unrelated donors to alloimunized patients. Ann Intern Med 80: 9–14, 1974.PubMedGoogle Scholar
  50. 50.
    Duquesnoy RJ, Filip DJ, Rodey GE et al.: Successful transfusion of platelets ‘mismatched’ for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hemat 2: 219–226, 1977.PubMedCrossRefGoogle Scholar
  51. 51.
    Aster RH: Matching of blood platelets for transfusion. Am J Hemat 5: 373–378, 1978.PubMedCrossRefGoogle Scholar
  52. 52.
    Gmur J, von Feiten A, Frick P: Platelet support in polysensitized patients: role of HLA specificities and crossmatch testing for donor selection. Blood 51: 903–909, 1978.PubMedGoogle Scholar
  53. 53.
    Opelz G, Mickey MR, Terasaki PI: Unrelated donors for bone-marrow transplantation and transfusion support: pool sizes required. Transpl Proc 6: 405–409, 1974.Google Scholar
  54. 54.
    Duquesnoy RJ, Vieira J, Aster RH: Donor availability for platelet transfusion support of alloimmunized thrombocytopenic patients. Transpl Proc 9: 519–521, 1977.Google Scholar
  55. 55.
    Duquesnoy RJ, Filip DJ, Rodey GE et al.: Successful transfusion of platelets ’mismatched’ for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hemat 2: 219–226, 1977.PubMedCrossRefGoogle Scholar
  56. 56.
    Duquesnoy RJ, Filip DJ, Aster RH: Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood 50: 407–412, 1977.PubMedGoogle Scholar
  57. 57.
    McElligott MC, Menitove JE, Duquesnoy RJ, Hunter JB, Aster RH: Effect of HLA Bw4/Bw6 compatibility on platelet transfusion responses of refractory thrombocytopenic patients. Blood 59: 971–975, 1982.PubMedGoogle Scholar
  58. 58.
    Duquesnoy RJ, Anderson AF, Tomasulo PA, Aster RH: ABO compatibility and platelet transfusions to alloimmunized thrombocytopenic patients. Blood 54: 595–599, 1979.Google Scholar
  59. 59.
    Tosato G, Applebaum FR, Deisseroth AB: HLA-matched platelet transfusion therapy of severe aplastic anemia. Blood 52: 846–854, 1978.PubMedGoogle Scholar
  60. 60.
    Duquesnoy RJ, Filip DJ, Tomasulo PA, Aster RH: Role of HLA-C matching in histocom- patible platelet transfusion therapy of alloimmunized thrombocytopenic patients. Transpl Proc 9: 1827–1828, 1977.Google Scholar
  61. 61.
    Mueller-Eckhardt G, Hauck M, Kayer W, Mueller-Eckhardt C: HLA-C antigens on platelets. Tissue Antigens 16: 91–94, 1980.PubMedCrossRefGoogle Scholar
  62. 62.
    Aster RH, Szatkowski N, Liebert M, Duquesnoy RJ: Expression of HLA-B12, HLA-B8, w4, and w6 on platelets. Transpl Proc 9: 1695–1696, 1977.Google Scholar
  63. 63.
    Thorsby E, Helgesen A, Gjemdal T: Repeated platelet transfusions from HL-A compatible unrelated and sibling donors. Tissue Antigens 2: 397–404, 1972.PubMedCrossRefGoogle Scholar
  64. 64.
    Daly PA, Simon R, Schiffer C et al.: A study of HLA antigens and haplotypes in a population of Caucasians with acute non-lymphocytic leukemia. Leuk Res 3: 75–82, 1979.PubMedCrossRefGoogle Scholar
  65. 65.
    Kahn RA, Harmon JA, Miller MV: Detection of platelet antibodies. In: A Seminar on Immune Mediated Cell Destruction, Bell CA (ed). Amer Assoc Blood Banks, Wash, DC, 1981, pp 151–198.Google Scholar
  66. 66.
    Dixon R, Rosse W, Ebbert L: Quantitative determination of antibody in idiopathic thrombocytopenic purpura. N Engl J Med 292: 230–236, 1975.PubMedCrossRefGoogle Scholar
  67. 67.
    Kr. von dem Borne AEG, Verheugt FWA, Oosterhof F et al.: A simple immunofluorescence test for the detection of platelet antibodies. Brit J Haemat 39: 195–207, 1978.CrossRefGoogle Scholar
  68. 68.
    Cines DB, Schreiber AD: Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med 300: 106–111, 1979.PubMedCrossRefGoogle Scholar
  69. 69.
    Gudino M, Miller WV: Application of the enzyme linked immunospecific assay (ELISA) for the detection of platelet antibodies. Blood 57: 32–37, 1981.PubMedGoogle Scholar
  70. 70.
    Myers TJ, Kim BK, Steiner M, Baldini MG: Selection of donor platelets for alloimmunized patients using a platelet-associated IgG assay. Blood 58: 444–450, 1981.PubMedGoogle Scholar
  71. 71.
    Slichter SJ: Selection of compatible platelet donors. In: Platelet Physiology & Transfusion, Schiffer CA (ed). Amer Assoc Blood Banks, Wash, DC, 1978, pp 83–92.Google Scholar
  72. 72.
    Batchelor JR, Welsh KI, Burgos H: Transplantation antigens per se are poor immunogens within a species. Nature 273-4–56, 1978.Google Scholar
  73. 73.
    Claas FHJ, Smeenk RJT, Schmidt R, van Steenbrugge GJ, Eernisse JG: Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 9: 84–89, 1981.PubMedGoogle Scholar
  74. 74.
    Welsh KI, Burgos H, Batchelor JR: The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking la. Eur J Immunol 7: 263–267, 1977.CrossRefGoogle Scholar
  75. 75.
    Storb R, Deeg HG, Weiden PL et al.: Marrow graft rejection in DLA-identical canine littermates: antigens involved are expressed on leukocytes and skin epithelial cells but probably not on platelets and red blood cells. Transpl Proc 9: 504–506, 1979.Google Scholar
  76. 76.
    Dausset J, Rapaport FT: Transplantation antigen activity of human blood platelets. Transplantation 4: 182–193, 1966.PubMedCrossRefGoogle Scholar
  77. 77.
    Eernisse JG, Brand A: Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 9: 77–83, 1981.PubMedGoogle Scholar
  78. 78.
    O’Donnell MR, Slichter SJ: Platelet (PLT) alloimmunization - correlation with donor source. Clin Res 27: 390, 1979.Google Scholar
  79. 79.
    Schiffer CA, Slichter SJ: Platelet transfusions from single donors. N Engl J Med 307: 245–248, 1982.PubMedCrossRefGoogle Scholar
  80. 80.
    Schiffer CA, Aisner J, Wiernik PH: Frozen autologous platelet transfusion for patient with leukemia. N Engl J Med 299: 7–12, 1978.PubMedCrossRefGoogle Scholar
  81. 81.
    Schiffer CA, Aisner J, Dutcher JR, Daly PA, Wiernik PH: A clinical program of platelet cryopreservation. In: Cytopheresis and Plasma Exchange: Clinical Indications, Vogler WR (ed). Alan R. Liss Inc, 1982, pp 165–180.Google Scholar
  82. 82.
    Schiffer CA, Dutcher J, Aisner J et al.: A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 60: 182a, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1983

Authors and Affiliations

  • Charles A. Schiffer

There are no affiliations available

Personalised recommendations